Skip to main content
Go to homepage

STOP2 – Standardized Treatment of Pulmonary Exacerbations

Description:

For complete study information, view the study on clinicaltrials.gov

Who May Qualify?:

Patients with Cystic Fibrosis ≥ 18 years of age planned to initiate intravenous (IV) antibiotics for a pulmonary exacerbation

Who Does Not Qualify:

Patients who have been treated with IV antibiotics within 6 weeks prior to Visit 1

Interested in participating?
We are currently recruiting
Study Sponsor:

CFFT Therapeutics Development Network Coordinating Center (TDNCC)

Full IRB Study Title:
Standardized Treatment of Pulmonary Exacerbation II (STOP2) Protocol No: STOP2-IP-15
IRB Study ID:
966544-18
If you are interested in this study or have questions about your child's eligibility, please contact:

For more information, contact: Brenda Bourne 330-543-3510 or Michelle Powers 330-543-3089

Lead Investigator
Gregory Omlor, MD, FAAP

Director, Lewis H Walker CF Center; Pediatric Pulmonologist
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Center